When was Syntis founded?

Syntis was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Syntis located?

Syntis is headquartered in Boston, United States.

How many employees does Syntis have?

As of Jul 31, 2026, the latest employee count at Syntis is 29.

Is Syntis a funded company?

Syntis is a funded company, having raised a total of $65.9M across 10 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 17, 2022.

When was the latest funding round of Syntis?

Syntis' latest funding was a $***** Grant (prize money) round on Sep 17, 2025, with participation from 1 investor.

Where does Syntis rank among its competitors?

Syntis ranks 4th amongst 43 active competitors, of which 16 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Hero Patch, which secured $12.6M in May, 2026.

Who are the top competitors of Syntis?

Syntis' top competitors include Kailera, Metsera and Zealand Pharma. Among them, Hero Patch secured the most recent funding round in May, 2026.

Syntis - 2026 Company Profile, Team, Funding & Competitors

Syntis is a series A company based in Boston (United States), founded in 2021 by Rahul Dhanda, C Giovanni Traverso and Robert Langer. It operates as a Provider of drug compounding services. Syntis has raised $65.9M in funding from Cerberus Capital Management. The company has 43 active competitors, including 16 funded and 7 that have exited. Its top competitors include companies like Kailera, Metsera and Zealand Pharma.

Company Details

Website: syntis.bio
Social
Email ID: *****@syntis.bio
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Boston, United States

Stage

Series A

Total Funding

$65.9M in 10 rounds

Latest Funding Round

Grant (prize money), Sep 17, 2025, $*****

Investors

Cerberus Capital Management & 11 more

Ranked

4^th among 43 active competitors

Employee Count

29 as on Jul 31, 2026

Similar Companies

Kailera & 44 more

View Syntis' full profile

Syntis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Syntis Bio, Inc. CIN: 1943061 , United States, Active		-	-	-

Syntis has raised a total funding of $65.9M over 10 rounds. Its first funding round was on Aug 17, 2022. Its latest funding round was a Grant (prize money) round on Sep 17, 2025 for $*****. 1 investor participated in its latest round. Syntis has 12 institutional investors.

Here is the list of recent funding rounds of Syntis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 17, 2025	7770508	Grant (prize money)	1603071	7906084	9151476	3799470
Jul 23, 2025	9450119	Grant (prize money)	4016658	3954873	5339920	HHS
Jul 02, 2025	8417555	Grant (prize money)	6665591	6763534	5298817	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Syntis's funding rounds and investors

The founders of Syntis are Rahul Dhanda, C Giovanni Traverso and Robert Langer. Rahul Dhanda is the CEO of Syntis.

Here are the details of Syntis' key team members:

Rahul Dhanda: Co-Founder & CEO of Syntis. They serve on the board of 1 company.
C Giovanni Traverso: Co-Founder of Syntis and founder of 6 other companies, including Teal Bio, Suono Bio and Celero Systems.
Robert Langer: Co-Founder of Syntis.

View details of Syntis's Founder profiles and Board Members

Syntis' employee count trend

Syntis has 29 employees as of Jul 26. Here is Syntis's employee count trend over the years:

Uncover Syntis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Syntis include Kailera, Metsera and Zealand Pharma. Here is the list of Top 10 competitors of Syntis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	65/100
2nd	Metsera 2022, New York City (United States), Acquired	Biopharmaceutical company focusing on medicines for obesity and metabolic diseases	$505M	Wellington, Arch Venture Partners & 16 others	61/100
3rd	Zealand Pharma 1998, Glostrup (Denmark), Public	Developer of protein therapies for the treatment of diabetes and gastrointestinal diseases	-	Oberland Capital, Athyrium Capital Management ... & 9 others	59/100
4th	Syntis 2021, Boston (United States), Series A	Provider of drug compounding services	$65.9M	Bold Capital Partners, Cerberus Capital Management ... & 10 others	57/100
5th	Skye Bioscience 2011, San Diego (United States), Public	Developer of cannabinoid-based therapies for the treatment of glaucoma and other diseases	$1.97M	Hilco Vision, Ally Bridge Group & 6 others	57/100
6th	CORXEL 2001, Berkeley Heights (United States), Series D	Developer of therapies for patients with cardiometabolic conditions	$287M	Hengdian Capital, RA Capital Management & 8 others	56/100
7th	Hero Patch 2019, Boston (United States), Series A	Developer of antibodies or small molecules for drug delivery	$20.5M	Big Pi Ventures, Velocity Partners & 5 others	55/100
8th	Resalis Therapeutics 2021, Turin (Italy), Series A	Developer of therapeutics for metabolic, oncology, and liver disease	$21.6M	Sunstone, Claris Ventures & 4 others	54/100
9th	Carmot 2008, Berkeley (United States), Acquired	Developer of disease-modifying therapies to treat metabolic diseases	$386M	The Column Group, Deep Track Capital & 17 others	53/100
10th	Zhejiang Daoer Biological Technology 2014, Hangzhou (China), Series A	Developer of protein therapies for metabolic diseases and cancers	$14.9M	Zhejiang Huarui Investment Holdings, Kaitai Capital Management ... Read more	49/100